Notably, overexpression of TPX2 led to increased PARP1 activity and thus to increased PARP trapping potential, providing an explanation for why high TPX2 mRNA levels in cancer cells correlate with increased sensitivity to PARP trapping inhibitors. The gene discussed is PARP1; the disease is cancer.